Compare CATX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATX | ADCT |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 136.1M |
| IPO Year | 2018 | 2019 |
| Metric | CATX | ADCT |
|---|---|---|
| Price | $0.86 | $1.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $9.43 | $3.33 |
| AVG Volume (30 Days) | ★ 4.2M | 1.2M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $91.56 | $25.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.78 | $0.78 |
| 52 Week High | $6.16 | $4.98 |
| Indicator | CATX | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 27.07 | 44.89 |
| Support Level | $0.78 | $0.97 |
| Resistance Level | $2.40 | $1.45 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 14.51 | 18.40 |
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).